EHA2023レポート⑥ 注目演題

前治療歴のないCLLに対するべネトクラクス＋オビヌツズマブ：
CLL14試験の6年間の結果 VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY (#S145)

Othman Al-Sawaf（University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany）